Imvax to Present Safety Data on Lead Program, IGV-001, at 2024 SNO Annual Meeting
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc. today announced an oral presentation and two poster presentations at the 2024 SNO Annual Meeting in Houston, Texas.
Imvax
Business Services · Pennsylvania, United States · 48 Employees
View Company Info for Free
About
Headquarters
601 Walnut St Ste 440W, Philadelphia, Pennsylva...Phone Number
(267) 900-4110Website
www.imvax.comRevenue
$10.1 MillionIndustry
Most Recent Scoops
Nov 10 2023
Event
Sep 6 2023
Executive Move
Highlights
$166.7M
Total Funding Amount
-
Most Recent Funding Amount
5
Number of Funding Rounds
Who is Imvax
Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax's portfolio includes several programs designed to stimulate a patient's immune system against the entire antigen signature of their tumor. Imvax's most advanced program is IGV-001 for the treatment of glioblastoma.Read more
Imvax Org Chart
Is Imvax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Imvax launches new products
Check out if Imvax is spiking on competitors!
Earning: See what the market has to say on Imvax recently announced quarterly report
Click to see if Imvax had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Imvax has new funding data
Check if Imvax has recently received funding, and reach out quickly before it becomes old news!
Imvax, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Imvax
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Imvax
Compare insights from companies similar to Imvax, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Imvax
$10.1M
48
Imvax financials insights
Gather financial insights about Imvax, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Imvax Employee Growth Rate
View Imvax’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Imvax Tech Stack
A closer look at the technologies used by Imvax
See more technologies
Most Recent Scoops
Nov 10 2023
Event
Events
Sep 6 2023
Executive Move
Board of Directors
Sep 6 2023
Executive Move
Board of Directors
Sep 6 2023
Funding
May 17 2022
New Hire
Executive Move
Jeff Geibel has joined the organization as Head of Information Technology.
Executive Moves, New Hire
Imvax News & Media
Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the completion of enrollment in its randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM). IGV-001 is derived from Imvax’s proprietary Goldspire™ immuno-oncology platform, which is designed to use a patient’s own tumor cells to induce a broad anEBCI Brings Awareness to How Newly Diagnosed Glioblastoma Patients Can Access Imvax’s Clinical Study
The End Brain Cancer Initiative (EBCI) Brings Awareness to How Newly Diagnosed Glioblastoma Patients Can Access Imvax’s Clinical Study REDMOND, WA, UNITED STATES, January 16, 2024 /EINPresswire.com/ -- The End Brain Cancer Initiative (EBCI) Brings …Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its Lead Program, IGV-001, in Newly Diagnosed Glioblastoma
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc. today announced details of its two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting.Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc. today announced two poster presentations at the 2023 SNO Annual Meeting in Vancouver, Canada, from November 15-19, 2023.
Read more news
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Imvax
Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax's portfolio includes several programs designed to stimulate a patient's immune system against the entire antigen signature of their tumor. Imvax's most advanc... Read More
